Abstract
Sickle cell disease (SCD) is caused by a mutation in the HBB gene, resulting in sickle hemoglobin (HbS), which, under hypoxia, polymerizes, deforming red blood cells and causing vaso-occlusive crises (VOCs) and severe complications. The induction of fetal hemoglobin (HbF) by hydroxyurea (HU) is an effective therapeutic strategy as it inhibits HbS polymerization. However, traditional monit…